APL-3007, pegcetacoplan (APL-2)

Phase 2

Biogen Inc. (BIIB)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

BIIBPhase 2$33.1B

APL-3007, pegcetacoplan (APL-2) Phase 2 Est. Readout

APL-3007, pegcetacoplan (APL-2)• Geographic Atrophy Secondary to Age-related Macular Degeneration240

Q2 2027~QConfirmed

CT.gov

00%

Competitive Landscape

2 competitors in Geographic Atrophy Secondary to Age-related Macular Degeneration

APLSPEGCETACOPLAN (APL-2)

Phase 3

APLSAPL-3007, pegcetacoplan (APL-2)

Phase 2

View Full Landscape

Drug Information

Target Indication

Geographic Atrophy Secondary to Age-related Macular Degeneration

Clinical Trial

NCT07215390

Last updated: 10/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

BIIB

Biogen Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

dimethyl fumaratePhase 3

Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

FSGS

C3G

Muscular Atrophy, Spinal

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts